FDA Approves Femara as First-Line Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

EAST HANOVER, NJ-Novartis Oncology has announced that the FDA has approved Femara (letrozole tablets) for the first-line treatment of postmenopausal women with hormone-receptor-positive or hormone-receptor-unknown, locally advanced or metastatic breast cancer. Most postmenopausal women with advanced breast cancer fall into these tumor-receptor categories, the company said in a news release.

EAST HANOVER, NJ—Novartis Oncology has announced that the FDA has approved Femara (letrozole tablets) for the first-line treatment of postmenopausal women with hormone-receptor-positive or hormone-receptor-unknown, locally advanced or metastatic breast cancer. Most postmenopausal women with advanced breast cancer fall into these tumor-receptor categories, the company said in a news release.

Letrozole, an aromatase inhibitor, is a once-a-day oral treatment that was first approved in 1997 for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Approval of the new indication followed a priority review by the FDA and a unanimous recommendation from the FDA’s Oncology Drugs Advisory Committee.

The recommendation was based on data from the largest single study ever to evaluate a hormonal therapy in this setting. Letrozole proved significantly more effective than tamoxifen (Nolvadex) in multiple efficacy endpoints.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content